Learn about the many ongoing clinical trials for prostate cancer leveraging PARP inhibitors combined with a variety of agents including AR-directed therapy, immunotherapy, and other targeted agents.
Download these slides from a live Webinar to gain expert insight on the rationale for combining PARP inhibitors and AR-directed therapy in mCRPC including the latest evidence from ASCO GU 2021.
This downloadable slide set from a live Webinar explores the rationale for combining PARP inhibitors with different types of agents for advanced prostate cancer, including immunotherapy, targeted agents, and radionuclides, incorporating the latest evidence from ASCO GU 2021.
Download these slides from a live Webinar to review the most recent clinical data on single-agent PARP inhibitors in metastatic castration-resistant prostate cancer
Download this brief summary slideset from a live Webinar to review the rationale for and most recent clinical data on PARP inhibitor combination therapy in metastatic CRPC.
In this commentary, 2 experts discuss the potential for PARP inhibitor combinations as neoadjuvant therapy and in the setting of metastatic castration-sensitive disease.
In this podcast episode, listen to Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, as they answer questions from a healthcare professional audience on the use of PARP inhibitors and PARP inhibitor combinations for patients with prostate cancer.
Download this short summary of key takeaways from a podcast on PARP inhibitors and PARP inhibitor combinations in prostate cancer.